Cardiac arrhythmia

Avive Partners with RapidSOS to Create a New Paradigm for Cardiac Arrest Response

Retrieved on: 
Tuesday, August 3, 2021
Medicine, Medical emergencies, Cardiac arrhythmia, Clinical medicine, Medical specialties, Cardiology, Cardiac arrest, Cardiopulmonary resuscitation, Chain of survival, Emergency medical services, Advanced cardiac life support

Cardiac arrest is one of the leading causes of death outside the hospital globally.

Key Points: 
  • Cardiac arrest is one of the leading causes of death outside the hospital globally.
  • While Cardiopulmonary Resuscitation ("CPR") "buys time," a person in cardiac arrest ultimately needs to receive a shock delivered from an AED to survive.
  • However, the greatest challenge with cardiac arrest emergencies is time, as every minute a person in cardiac arrest goes without receiving a defibrillation shock reduces their chances of survival by 7-10%.
  • Together with our RapidSOS Ready emergency community, RapidSOS is supporting first responders in saving millions of lives annually.

MindMics Announces Results from a Clinical Trial of Revolutionary Earbuds Technology -- In-ear Infrasonic Hemodynography - to Achieve Cardiac Arrhythmia Assessment beyond that of ECG

Retrieved on: 
Monday, August 2, 2021
Branches of biology, Medicine, Cardiac arrhythmia, Clinical medicine, Cardiac electrophysiology, Medical emergencies, Atrial fibrillation, Electrocardiography, Arrhythmia, Clinical cardiac electrophysiology, Michel Haïssaguerre

CAMBRIDGE, Mass., Aug. 2, 2021 /PRNewswire/ - MindMics, Inc. reported results from the clinical trial of revolutionary earbuds that make use of a new technology -- in-ear infrasonic hemodynography (IH) - for the monitoring of cardiac arrhythmias, resulting in insights beyond those that have been possible with state-of-the-art ECG monitoring. These results were presented at the Heart Rhythm Society meeting in Boston, July 30, 2021.

Key Points: 
  • The clinical trial for recruiting atrial fibrillation (AF) patients was approved by the institutional review board of The University of South Carolina School of Medicine.
  • Synchronized MindMics In-ear Infrasonic Hemodynography (IH) data and ECG were simultaneously recorded from 15 patients in AF and 15 in SR for 20 minutes.
  • Recruited AF patients were between the ages of 45 years and 90 years and showed a variety of arrhythmias.
  • An oral presentation titled "MindMics: In-ear Infrasonic Hemodynography For Cardiac Arrhythmia Assessment Beyond ECG"was given at the Heart Rhythm Society 2021 Annual Meeting: Bringing the World of EP (Electrophysiology) Together on July 28-31.

AtriCure to Participate at the Canaccord 41st Annual Growth Conference

Retrieved on: 
Friday, July 30, 2021
Hospitals, Health, Cardiology, Medical devices, Medical specialties, Surgery, Medicine, Cardiac arrhythmia, Atrial fibrillation, Cardiothoracic surgery, Atrium, Atrial appendage, Complication

AtriCure, Inc. ( Nasdaq: ATRC ), a leading innovator in surgical treatments for atrial fibrillation (Afib) and left atrial appendage (LAA) management, today announced that the company will be participating in the upcoming Canaccord 41st Annual Growth Conference.

Key Points: 
  • AtriCure, Inc. ( Nasdaq: ATRC ), a leading innovator in surgical treatments for atrial fibrillation (Afib) and left atrial appendage (LAA) management, today announced that the company will be participating in the upcoming Canaccord 41st Annual Growth Conference.
  • Interested parties may access a live and archived audio webcast of the presentation by visiting the Investors section of the companys website at https://ir.atricure.com .
  • AtriCure, Inc. provides innovative technologies for the treatment of Afib and related conditions.
  • Electrophysiologists and cardiothoracic surgeons around the globe use AtriCure technologies for the treatment of Afib and reduction of Afib related complications.

iRhythm Technologies to Report Second Quarter 2021 Financial Results on August 5, 2021

Retrieved on: 
Thursday, July 22, 2021
Medical emergencies, Arrhythmia, Heart, Cardiac arrhythmia

SAN FRANCISCO, July 22, 2021 (GLOBE NEWSWIRE) -- iRhythm Technologies, Inc. (NASDAQ: IRTC), a leading digital health care solutions company focused on the advancement of cardiac care, today announced that it will release financial results for the second quarter 2021 after the close of trading on Thursday, August 5, 2021.

Key Points: 
  • SAN FRANCISCO, July 22, 2021 (GLOBE NEWSWIRE) -- iRhythm Technologies, Inc. (NASDAQ: IRTC), a leading digital health care solutions company focused on the advancement of cardiac care, today announced that it will release financial results for the second quarter 2021 after the close of trading on Thursday, August 5, 2021.
  • The companys management team will host a corresponding conference call beginning at 1:30 p.m. PT / 4:30 p.m.
  • iRhythm is a leading digital health care company redefining the way cardiac arrhythmias are clinically diagnosed.
  • The company believes improvements in arrhythmia detection and characterization have the potential to change clinical management of patients.

CardioFocus to Exhibit and Present Data Supporting HeartLight X3 System at Heart Rhythm 2021

Retrieved on: 
Monday, July 19, 2021
Cardiac arrhythmia, Catheter ablation, PVI, Catheter, Atrial fibrillation, Heartlight

CardioFocus will be anchored at Heart Rhythm 2021 in Booth 310, boasting 900 square feet of exhibition space with four monitors and two interactives for attendees.

Key Points: 
  • CardioFocus will be anchored at Heart Rhythm 2021 in Booth 310, boasting 900 square feet of exhibition space with four monitors and two interactives for attendees.
  • The HeartLight X3 System is a revolutionary catheter ablation technology for controlled and consistent pulmonary vein isolation (PVI), the gold standard treatment for atrial fibrillation (AFib).
  • Using direct tissue visualization, titratable laser energy and compliant balloon technology, the HeartLight X3 System is a truly differentiated PVI solution.
  • The HeartLight X3 catheter, endoscope, sheath, console and balloon fill media are all manufactured in theUSA.

OneProjects, VistaMed and Tyndall Institute Awarded Funding to Improve Treatment of Cardiac Arrhythmias

Retrieved on: 
Wednesday, July 14, 2021
Biotechnology, Medical devices, Health, Cardiology, Medical Supplies, Cardiac arrhythmia, Circulatory system, Cardiovascular system, Branches of biology, Atrial fibrillation, Catheter ablation, Arrhythmia, Fibrillation, Cardiac electrophysiology, Michel Haïssaguerre, Minimaze procedure, Freudenberg Medical, OneProjects, FREUDENBERG MEDICAL, ONEPROJECTS

Atrial fibrillation or AFib is an irregular heartbeat or cardiac arrhythmia which can lead to blood clots, stroke, and heart failure.

Key Points: 
  • Atrial fibrillation or AFib is an irregular heartbeat or cardiac arrhythmia which can lead to blood clots, stroke, and heart failure.
  • First procedure success rates for patients with atrial fibrillation undergoing cardiac ablation can be as low as 50% and OneProjects aims to increase this significantly.
  • A consortium of three partners were awarded the grant, led by the medical device company, OneProjects with the Tyndall National Institute and VistaMed / Freudenberg Medical .
  • The resulting platform technology will achieve better patient outcomes treating millions of people worldwide who suffer with cardiac arrhythmias, said Patrick Mulholland, Managing Director at VistaMed.

Global StopAfib.org Virtual Atrial Fibrillation Patient Conference, August 6-8

Retrieved on: 
Tuesday, July 13, 2021
Cardiac arrhythmia, Branches of biology, Atrial fibrillation, Circulatory system, Cardiovascular system, Fibrillation, Arrhythmia, Stroke, Familial atrial fibrillation, XEN-D0101

Virtual Atrial Fibrillation Patient Conference is for those living with atrial fibrillation (afib), the most common irregular heartbeat, which increases stroke risk by 500%.

Key Points: 
  • Virtual Atrial Fibrillation Patient Conference is for those living with atrial fibrillation (afib), the most common irregular heartbeat, which increases stroke risk by 500%.
  • Atrial Fibrillation Patient Conference.
  • "Our annual patient conference is a labor of love and a gift," said Mellanie True Hills, founder of StopAfib.org.
  • Virtual Atrial Fibrillation Patient Conference is open.

AtriCure to Announce Second Quarter 2021 Financial Results

Retrieved on: 
Wednesday, July 7, 2021
Hospitals, Health, Cardiology, Medical devices, Medical specialties, Surgery, Anatomy, Cardiac arrhythmia, Atrial fibrillation, Surgical specialties, Atrium, Atrial appendage, Cardiothoracic surgery, Laa

AtriCure, Inc. ( Nasdaq: ATRC ), a leading innovator in treatments for atrial fibrillation (Afib) and left atrial appendage (LAA) management, today announced that it will release second quarter 2021 financial results on Wednesday, August 4, 2021.

Key Points: 
  • AtriCure, Inc. ( Nasdaq: ATRC ), a leading innovator in treatments for atrial fibrillation (Afib) and left atrial appendage (LAA) management, today announced that it will release second quarter 2021 financial results on Wednesday, August 4, 2021.
  • AtriCure will host a conference call at 4:30 p.m. Eastern Time on Wednesday, August 4, 2021 to discuss its second quarter 2021 financial results.
  • A live audio webcast of the presentation may be accessed by visiting the Investors page of AtriCures corporate website at ir.atricure.com .
  • Electrophysiologists and cardiothoracic surgeons around the globe use AtriCure technologies for the treatment of Afib and reduction of Afib related complications.

New Study Evaluates the Ability of Masimo SedLine® Brain Function Monitoring to Predict Neurological Outcomes and Long-term Survival in Post-Cardiac Arrest ICU Patients

Retrieved on: 
Tuesday, July 6, 2021
Medical devices, Health, Hospitals, Practice Management, Clinical trials, General Health, Cardiac arrest, Cardiac arrhythmia

Neurological outcomes were categorized using the Pittsburgh Brain Stem Score (PBSS) and Cerebral Performance Category (CPC).

Key Points: 
  • Neurological outcomes were categorized using the Pittsburgh Brain Stem Score (PBSS) and Cerebral Performance Category (CPC).
  • The researchers concluded that PSi and SR are good predictors for early neuro-prognostication in post-cardiac arrest patients.
  • They also noted, The combination of PSI and SR showed better predictability of poor neurologic outcome than did each individual parameter.
  • Our mission is to improve patient outcomes, reduce the cost of care, and take noninvasive monitoring to new sites and applications.

CardioFocus Appoints Stephan Ogilvie as Chief Financial Officer

Retrieved on: 
Tuesday, June 29, 2021
Cardiac arrhythmia, NuVasive, Atrial fibrillation, Ogilvie, Ablation

MARLBOROUGH, Mass., June 29, 2021 /PRNewswire/ -- CardioFocus, Inc. , a medical device company dedicated to advancing ablation treatment for atrial fibrillation (AFib), today announced the appointment of Stephan Ogilvie as its Chief Financial Officer.

Key Points: 
  • MARLBOROUGH, Mass., June 29, 2021 /PRNewswire/ -- CardioFocus, Inc. , a medical device company dedicated to advancing ablation treatment for atrial fibrillation (AFib), today announced the appointment of Stephan Ogilvie as its Chief Financial Officer.
  • Previously Mr. Ogilvie served as Vice President, Corporate Development at NuVasive, where he led a variety of key functions, including mergers and acquisitions and the expansion of the company's global sales infrastructure.
  • "Steve possesses deep experience in the healthcare industry, including a diverse background across key operational roles at medical device companies, as well as within the medical device sector on Wall Street," said Burke T. Barrett, chief executive officer and president of CardioFocus.
  • "CardioFocus is bringing important innovation to the Afib ablation space with its recently launched HeartLight X3," said Mr. Ogilvie.